SPRO (Spero Therapeutics) ROCE %: -53.09% (As of Mar. 2026)

What is Spero Therapeutics ROCE %?

Spero Therapeutics SPRO -4.04% 55 ROCE % is -53.09% as of Mar. 2026. GuruFocus rates SPRO with a GF Score™ of 55/100 and a GF Value™ of $1.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Spero Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -53.09%.

Spero Therapeutics (NAS:SPRO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Spero Therapeutics ROCE % Related Terms

Spero Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics ROCE % Chart

Spero Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-60.25

-34.29

21.57

-70.13

11.78

Spero Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-105.84	-19.73	-66.86	249.81	-53.09

55GF Score

Spero Therapeutics Inc SPRO

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Spero Therapeutics ROCE % Calculation

Spero Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	7.159	/	( ( (110.543 - 49.074)	+	(68.919 - 8.868) )	/ 2 )
	=	7.159	/	( (61.469	+	60.051)	/ 2 )
	=	7.159	/	60.76
	=	11.78 %

Spero Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-30.152	/	( ( (68.919 - 8.868)	+	(59.021 - 5.489) )	/ 2 )
	=	-30.152	/	( ( 60.051	+	53.532 )	/ 2 )
	=	-30.152	/	56.7915
	=	-53.09 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -53.09% mean?

Spero Therapeutics (SPRO) has a ROCE % of -53.09% as of Mar. 2026.

Is Spero Therapeutics' ROCE % too high?

Spero Therapeutics' current ROCE % is -53.09%. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Spero Therapeutics' ROCE % compare to ORMP and PLYX?

Spero Therapeutics' ROCE % of -53.09% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Spero Therapeutics's current ROCE % is -53.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Spero Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $2.02 — trading 90.6% above its estimated fair value. The current ROCE % is -53.09%. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current ROCE % is -53.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of $2.02 is trading 90.6% above its estimated GF Value™ of $1.06. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for SPRO:

ROCE %: -53.09%
GF Value™: $1.06 vs. price of $2.02 (90.6% above fair value)
GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spero Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ORMP PLYX HRTX MENS NRXP PRQR GALT PLX CNTB ANTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 2HA:Germany

Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

55GF Score

Get the complete analysis for SPRO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.02

Price

$1.06

GF Value

View SPRO Analysis

See ROCE % data for all stocks →